Halozyme Therapeutics, Inc. Financial Ratios — RV7 Stock

Profitability (USD)

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
As of date	12/31/2011	12/31/2012	12/31/2013	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025

Return on Common Equity (%)	-126.52	-179.24	- -	- -	-76.42	- -	- -	-35.14	-42.41	106.33	231.44	110.23	222.07	198.42	153.59
Return on Assets (%)	-25.17	-53.42	-70.59	-51.07	-18.54	-46.48	16.12	-16.73	-14.36	22.53	47.82	13.72	15.75	23.39	13.81
Return on Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	28.66	- -	15.7	18.21	26.56	16.21
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	27.67	- -	15.82	16.79	25.51	15.68
Gross Margin (%)	99.54	97.42	88.6	69.83	78.35	77.36	90.16	93.33	76.76	83.79	81.64	78.9	76.8	84.3	83.62
EBITDA Margin (%)	-33.42	-124.15	-144.54	-81.34	-19.08	-55.08	26.27	-44.08	-32.42	55.14	62.91	48.05	50.94	62.32	39.89
Operating Margin (%)	-35.37	-126.7	-146.78	-83.68	-20.33	-56.72	25.58	-45.65	-34.5	53.91	62.24	40.53	40.71	54.32	57.47
Incremental Operating Margin (%)	81.06	245.51	- -	84.72	59.58	- -	96.64	91.25	3.9	295.89	74.92	- -	41.41	114.96	65.86
Pretax Margin (%)	-35.25	-126.53	-152.34	-90.76	-23.86	-69.44	19.46	-52.54	-36.86	48.32	56.06	37.71	42.01	54.87	33.43
Profit Margin (%)	-35.25	-126.53	-152.34	-90.76	-23.86	-70.23	19.89	-52.9	-36.86	48.24	90.84	30.62	33.96	43.74	22.69
Net Income to Common Margin (%)	-35.25	-126.53	-152.34	-90.76	-23.86	-70.23	19.89	-52.9	-36.86	48.24	90.84	30.62	33.96	43.74	22.69
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	0.17	- -	18.8	19.16	20.29	32.13
Dvd Payout Ratio (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Sustainable Growth Rate (%)	-126.52	-179.24	- -	- -	-76.42	- -	- -	-35.14	-42.41	106.33	231.44	110.23	222.07	198.42	153.59

Credit (USD)

Credit Ratios API ChatGPT

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
As of date	12/31/2011	12/31/2012	12/31/2013	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025

Total Debt	- -	31	50	50	50	217	202	126	403	397	877	1,506	1,499	1,506	2,143
ST Debt	- -	- -	- -	- -	22	17	77	92	20	397	89	13	- -	- -	- -
LT Debt	- -	31	50	50	28	199	125	35	383	- -	787	1,493	1,499	1,506	2,143
Total Debt/EBITDA	- -	-0.59	-0.63	-0.81	-1.93	-2.68	2.43	-1.89	-6.34	2.69	3.14	4.75	3.55	2.38	3.85
Net Debt/EBITDA	2.82	1.33	-0.28	0.19	-0.25	-1.85	0.4	-1.02	-4.44	1.69	2.72	4.01	3.27	2.2	3.61
Total Debt/EBIT	- -	-0.58	-0.62	-0.79	-1.82	-2.6	2.5	-1.82	-5.95	2.75	3.18	5.63	4.44	2.73	4.57
Net Debt/EBIT	2.66	1.3	-0.28	0.18	-0.24	-1.8	0.41	-0.99	-4.18	1.73	2.75	4.75	4.09	2.52	4.28
EBITDA to Interest Expense	- -	- -	-24.19	-10.98	-4.96	-4.04	3.78	-3.71	-5.47	7.24	37.06	18.72	22.52	34.97	30.73
EBITDA-CapEx/Interest Expense	- -	- -	-24.89	-11.22	-5.41	-4.2	3.72	-3.97	-5.81	7.12	36.86	18.43	21.7	34.38	14.47
EBIT to Interest Expense	- -	- -	-24.57	-11.29	-5.28	-4.17	3.68	-3.84	-5.81	7.08	36.66	15.79	17.99	30.48	44.28
Interest Expense	- -	- -	3	6	5	20	22	18	12	20	8	17	19	18	18
Common Equity/Total Assets	16.58	36.26	-19.64	24.91	23.65	-12.42	40.07	56.53	16.22	26.05	17.83	9.22	4.84	17.63	1.93
Long-Term Debt/Equity (%)	- -	63.68	- -	120.57	65.05	- -	60.06	14.01	417.42	- -	399.72	879.14	1,788.91	413.88	4,389.38
Long-Term Debt/Capital (%)	- -	38.91	167.12	54.66	30.13	108.19	30.47	9.29	77.48	- -	73.33	89.07	94.71	80.54	97.77
Long-Term Debt/Total Assets (%)	- -	23.09	48.9	30.04	15.39	76.18	24.07	7.92	67.69	- -	71.28	81.06	86.5	72.97	84.85
Total Debt/Equity (%)	- -	63.68	-248.98	120.57	115.89	-666.92	97.11	50.78	438.72	262.98	445.12	887	1,788.91	413.88	4,389.38
Total Debt/Capital (%)	- -	38.91	167.12	54.66	53.68	117.64	49.27	33.68	81.44	72.45	81.66	89.87	94.71	80.54	97.77
Total Debt/Total Assets (%)	- -	23.09	48.9	30.04	27.41	82.83	38.92	28.71	71.14	68.5	79.38	81.79	86.5	72.97	84.85
Net Debt to Equity	-484.63	-142.96	-112.13	-27.88	15.21	-461.37	16.13	27.5	307.75	165.2	384.84	749.07	1,647.67	382.04	4,115.23
Net Debt/Capital (%)	126	357.49	924.33	-38.66	13.2	127.67	13.89	21.57	75.48	62.29	79.37	88.22	94.28	79.25	97.63
EBITDA	-19	-53	-79	-61	-26	-81	83	-67	-64	148	279	317	422	633	557
EBITDA-CapEx	-20	-54	-82	-63	-28	-84	82	-72	-68	145	277	312	407	622	262
Operating Income (Loss)	-20	-54	-80	-63	-27	-83	81	-69	-68	144	276	268	338	551	803

Liquidity (USD)

Liquidity Ratios API ChatGPT

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
As of date	12/31/2011	12/31/2012	12/31/2013	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025

Cash Ratio	3.05	5.25	2.87	5.57	1.73	3.76	3.57	2.37	4.92	0.87	6.32	2.77	2.99	4.29	0.81
Current Ratio	3.7	6.89	3.82	6.63	2.75	4.7	3.89	2.86	6.35	1.32	7.91	5.65	6.64	7.8	4.66
Quick Ratio	3.18	6.08	3.24	5.95	2.25	4.04	3.74	2.57	5.61	1.11	7.1	4.54	5.07	6.5	3.3
CFO/Avg Current Liab	-2.1	-3.55	-2.25	-1.93	-0.85	-0.86	1.44	-0.35	-0.73	0.22	1.11	1.94	3.19	3.81	4.12
Common Equity/Total Assets	16.58	36.26	-19.64	24.91	23.65	-12.42	40.07	56.53	16.22	26.05	17.83	9.22	4.84	17.63	1.93
Long-Term Debt/Equity (%)	- -	63.68	- -	120.57	65.05	- -	60.06	14.01	417.42	- -	399.72	879.14	1,788.91	413.88	4,389.38
Long-Term Debt/Capital (%)	- -	38.91	167.12	54.66	30.13	108.19	30.47	9.29	77.48	- -	73.33	89.07	94.71	80.54	97.77
Long-Term Debt/Total Assets (%)	- -	23.09	48.9	30.04	15.39	76.18	24.07	7.92	67.69	- -	71.28	81.06	86.5	72.97	84.85
Total Debt/Equity (%)	- -	63.68	-248.98	120.57	115.89	-666.92	97.11	50.78	438.72	262.98	445.12	887	1,788.91	413.88	4,389.38
Total Debt/Capital (%)	- -	38.91	167.12	54.66	53.68	117.64	49.27	33.68	81.44	72.45	81.66	89.87	94.71	80.54	97.77
Total Debt/Total Assets (%)	- -	23.09	48.9	30.04	27.41	82.83	38.92	28.71	71.14	68.5	79.38	81.79	86.5	72.97	84.85
CFO/Total Liabilities	-62.53	-74.85	-40.51	-38.13	-26.72	-17.14	43.02	-25.87	-18.02	12.93	33	14.36	23.56	28.19	26.31
CFO/CapEx	-41.4	-45.49	-21.48	-34.74	-15.71	-16.06	99.3	-10.62	-21.14	22.15	205.52	49.92	25.41	44.79	2.21
Altman's Z-Score	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -

Working Capital (USD)

Working Capital Ratios API ChatGPT

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
As of date	12/31/2011	12/31/2012	12/31/2013	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025

Accounts Receivable Turnover	24.43	4.67	4.28	7.74	6.26	5.91	16.27	5.7	4.32	3.37	4.65	4.7	3.87	3.78	3.82
Days Sales Outstanding	14.94	78.23	85.22	47.16	58.29	61.73	22.44	64.04	84.58	108.42	78.57	77.69	94.39	96.51	95.55
Inventory Turnover	0.68	0.68	1.41	3.62	3.68	2.75	3.15	0.73	1.75	0.96	1.42	1.81	1.69	1.18	1.44
Days Inventory Outstanding	538.43	540.15	258.31	100.96	99.19	132.52	115.81	500.02	208.3	379.19	257.02	201.79	216.05	308.48	253.95
Accounts Payable Turnover	0.11	0.65	3.6	7.48	8.62	9.49	3.76	4.59	9.95	17.88	42.99	19.29	14.9	15.74	16.91
Accounts Payable Turnover Days	3,287.04	560.98	101.25	48.77	42.35	38.45	97.05	79.48	36.7	20.41	8.49	18.92	24.5	23.19	21.58
Cash Conversion Cycle	-2,733.68	57.4	242.28	99.35	115.13	155.8	41.21	484.58	256.18	467.2	327.1	260.56	285.94	381.8	327.91
Inventory to Cash Days	-523.49	-461.92	-173.1	-53.8	-40.9	-70.79	-93.37	-435.98	-123.71	-270.77	-178.45	-124.11	-121.66	-211.97	-158.4
Inventories	1	3	6	6	9	15	5	23	29	61	54	100	128	142	176
Raw Materials	- -	1	1	1	1	1	- -	1	3	6	11	14	24	- -	- -
Work In Process	- -	1	4	5	8	13	2	11	16	34	17	40	34	- -	- -
Finished Goods	- -	1	1	1	- -	1	3	10	11	21	26	46	70	- -	- -
Other Inventory	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	142	176

Enterprise Value (USD)

Enterprise Value API ChatGPT

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
As of date	12/31/2011	12/31/2012	12/31/2013	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025

Market Capitalization	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
- Cash & Cash Equivalents	53	100	27	61	43	67	169	58	120	148	119	234	118	116	134
+ Preferred Equity and Hybrid Capital	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Minority/Non Controlling Interest	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Total Debt	- -	31	50	50	50	217	202	126	403	397	877	1,506	1,499	1,506	2,143
Enterprise Value	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Total Capital	11	80	30	91	93	184	411	375	494	548	1,074	1,676	1,583	1,870	2,191
Total Debt/Capital (%)	- -	38.91	167.12	54.66	53.68	117.64	49.27	33.68	81.44	72.45	81.66	89.87	94.71	80.54	97.77
Total Debt / EV	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/Sales	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/EBITDA	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/EBIT	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/Cash Flow to Firm	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/Free Cash Flow to Firm	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Diluted Market Cap	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Diluted Enterprise Value	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
TTM Sales	56	42	55	75	135	147	317	152	196	268	443	660	829	1,015	1,397
TTM EBITDA	-19	-53	-79	-61	-26	-81	83	-67	-64	148	279	317	422	633	557
TTM Operating Income	-20	-54	-80	-63	-27	-83	81	-69	-68	144	276	268	338	551	803
TTM Cash Flow to Firm	- -	- -	- -	- -	- -	- -	- -	- -	- -	76	- -	254	404	493	664
TTM Free Cash Flow to Firm	- -	- -	- -	- -	- -	- -	- -	- -	- -	73	- -	249	388	483	369

Multiples (USD)

Valuation Multiples API ChatGPT

No data availableFinancial data will appear here once available

Shares Outstanding	104	113	115	126	128	130	143	145	137	135	137	135	127	123	118
Diluted Weighted Avg Shares	103	111	113	123	127	128	139	144	144	141	147	141	134	129	124
Basic Weighted Avg Shares	103	111	113	123	127	128	136	144	144	136	141	137	132	127	120
Revenue per Share	0.55	0.38	0.49	0.61	1.07	1.15	2.32	1.06	1.36	1.96	3.15	4.82	6.29	8.01	11.65
EBITDA per Share	-0.18	-0.47	-0.7	-0.5	-0.2	-0.63	0.61	-0.47	-0.44	1.08	1.98	2.32	3.2	4.99	4.65
Operating Income per Share	-0.19	-0.48	-0.71	-0.51	-0.22	-0.65	0.59	-0.48	-0.47	1.06	1.96	1.96	2.56	4.35	6.7
Basic EPS, GAAP	-0.19	-0.48	-0.74	-0.56	-0.25	-0.81	0.46	-0.56	-0.5	0.95	2.86	1.48	2.13	3.5	2.64
Basic EPS from Cont Ops	-0.19	-0.48	-0.74	-0.56	-0.25	-0.81	0.46	-0.56	-0.5	0.95	2.86	1.48	2.13	3.5	2.64
Diluted EPS, GAAP	-0.19	-0.48	-0.74	-0.56	-0.25	-0.81	0.45	-0.56	-0.5	0.91	2.74	1.44	2.1	3.43	2.56
Diluted EPS from Cont Ops	-0.19	-0.48	-0.74	-0.56	-0.25	-0.81	0.45	-0.56	-0.5	0.91	2.74	1.44	2.1	3.43	2.56
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Cash Flow per Share	-0.33	-0.58	-0.44	-0.39	-0.29	-0.39	0.98	-0.34	-0.59	0.41	2.13	1.75	2.95	3.78	5.44
Free Cash Flow per Basic Share	-0.34	-0.59	-0.46	-0.4	-0.31	-0.42	0.97	-0.38	-0.62	0.39	2.12	1.72	2.83	3.69	2.98
Cash & Equivalents per Share	0.51	0.88	0.62	1.08	0.85	1.58	3.29	2.45	3.08	2.73	5.39	2.68	2.65	4.84	1.21
Book Value per Share	0.1	0.43	-0.17	0.33	0.34	-0.25	1.46	1.72	0.67	1.12	1.43	1.26	0.66	2.95	0.41
Tangible Book Value per Share	0.1	0.43	-0.17	0.33	0.34	-0.25	1.46	1.72	0.67	1.12	1.43	-5.81	-6.36	-3.69	-12.85

Halozyme Therapeutics, Inc.

Profitability (USD)

Credit (USD)

Liquidity (USD)

Working Capital (USD)

Enterprise Value (USD)

Multiples (USD)

Per Share Data Items (USD)